RU97113700A - APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF OBESITY - Google Patents

Claims (19)

1. The use of compounds of General formula I

in which R ¹ , R ⁴ and R ⁵ individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R ² and R ³ are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition for treating or preventing obesity. 2. The use according to claim 1, wherein said compound has general formula III

where R ¹ , R ² , R ³ , R ⁴ and R ⁵ each has the meaning given in paragraph 1. 3. The use according to claim 1 or 2, in which R ¹ is lower alkoxy, preferably methoxy. 4. The use according to any one of the preceding paragraphs, in which R ² represents lower alkyl, preferably methyl. 5. The use according to any one of the preceding paragraphs, in which R ³ represents lower alkyl, preferably methyl. 6. The use according to any one of the preceding paragraphs, in which R ⁴ represents hydrogen. 7. The use according to any one of the preceding claims, wherein R ⁵ is (tertiary amino) (lower alkoxy), preferably 2- (pyrrolidin-1-yl) ethoxy.  8. The use according to any one of the preceding claims, wherein said compound is a stereoisomer, for example, an isolated d- or 1-enantiomer.  9. The use according to any one of the preceding claims, wherein said compound is an isolated 1-enantiomer.  10. The use according to claim 1, wherein said compound is 3,4-trans-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy) phenyl] -7- methoxychroman.  11. The use according to the preceding paragraph, wherein said compound is an isolated 3, 4-trans-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy d-or 1-enantiomer ) phenyl] -7-methoxychroman.  12. The use according to claim 11, wherein said compound is 1-3,4-trans-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy) phenyl] - 7-methoxychroman.  13. The use according to any one of the preceding claims, wherein said composition is in a form suitable for oral administration.  14. The use according to any one of the preceding claims, wherein said compound is administered as a dose in the range from approximately 0.001 to 75, preferably in the range from approximately 0.01 to 75, more preferably in the range from approximately 0.01 to 50 and especially in the range of approximately 0.1 to 25 mg / kg of patient per day.  15. The use according to any one of the preceding claims, wherein said composition is applied one or more times a day or a week.  16. The use according to any one of the preceding claims, wherein said composition is in the form of a dermal implant.  17. A method of treating and preventing obesity, comprising administering to a patient a therapeutically effective amount of an anti-obesity compound of formula I, as claimed in any one of the preceding points of use, or a pharmaceutically acceptable salt thereof in an amount sufficient to treat or prevent obesity.  18. A method of treating or preventing obesity, the method comprising administering a therapeutically effective amount of a compound of formula I or a salt thereof and pharmaceutically acceptable compositions containing such a compound to a patient in need of such treatment.  19. Any new feature or combination of features described here.